Connect with us


Bharat Biotech’s COVID-19 Vaccine Covaxin Shows Encouraging Results In Clinical Trials: Research Paper

Bharat Biotech’s COVID-19 vaccine showed long-term antibody and T-cell memory responses, three months after the shot in phase 1 volunteers

Bharat Biotech’s COVID-19 Vaccine Covaxin Shows Encouraging Results In Clinical Trials: Research Paper
  • Bharat Biotech’s COVID-19 vaccine Covaxin is now undergoing phase-3 trial
  • Memory T-cells remain for long after an infection gets over: Expert
  • Covaxin can generate antibodies that may persist for 6-12 months: Experts

Hyderabad: Covaxin, a COVID-19 vaccine being developed by Bharat Biotech, showed long-term antibody and T-cell (immune) memory responses three months after the shot in phase 1 volunteers and tolerable safety outcomes in Phase 2study, the city-based company has said, suggesting the antibodies may persist for six to 12 months. In phase 2, it also showed enhanced humoral and cell-mediated immune responses and the results were found in the safety and immunogenicity clinical trial of the vaccine candidate.

Also Read: Mutation In Coronavirus Not Likely To Affect Vaccine Development: Council Of Scientific And Industrial Research

Memory T cells are antigen-specific T cells that remain over a long term after an infection has been eliminated. Covaxin, being developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology, is now undergoing phase-3 trials. In a double-blind, randomised, multi-centre phase 2clinical trials, a total of 380 healthy children and adults were randomised and administered two vaccine formulations in as many doses (four weeks apart).

In a follow-up of the phase 1 trial, Covaxin (BBV152)produced high levels of neutralising antibodies that remained elevated in all participants three months (at day 104) after the second vaccination. Based on these results, we hypothesise that BBV152 can generate antibodies that may persist for 6-12 months, Bharat Biotech said in a research paper on Covaxin. The results from the phase 2 study show that both humoral and cell-mediated responses were observed. No neutralising antibody differences were observed between sexes and across age groups. Covaxin was well tolerated in both dose groups with no serious adverse events, the research paper further said.

Also Read: India’s COVID-19 Vaccination Drive Will Be The Largest In The World: Fitch Solutions

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Folk Music For A Swasth India

Folk Music

Reckitt’s Commitment To A Better Future

India’s Unsung Heroes

Women’s Health

हिंदी में पड़े